Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBD-bFGF
- Development stage
- Unknown
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intrauterine
01
Overview
CBD-bFGF is a recombinant fusion protein consisting of basic fibroblast growth factor (bFGF, also known as FGF-2) fused to a collagen-binding domain (CBD). Developed by researchers led by Dr. Yali Hu at Nanjing Drum Tower Hospital, this biologic is designed to bind specifically to collagen scaffolds or the extracellular matrix of scarred tissues. By anchoring to the site of injury, it provides a sustained-release delivery system that promotes localized angiogenesis and tissue regeneration. It is primarily being investigated for the treatment of endometrial fibrosis, intrauterine adhesions (Asherman's syndrome), and thin endometrium to address female infertility caused by uterine scarring. In clinical trials, it is often administered via ultrasound-guided intrauterine injection, sometimes in conjunction with collagen scaffolds and bone marrow mononuclear cells (BMMNCs).
- Other names
- cannabidiol-basic fibroblast growth factorCollagen-binding basic fibroblast growth factorCollagen-binding domain-basic fibroblast growth factor fusion protein
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)
Beyond the preview
Go deeper on CBD-bFGF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBD-bFGF.